254 related articles for article (PubMed ID: 24744183)
1. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.
Xu S; Zhang Z; Ogawa O; Yoshikawa T; Sakamoto H; Shibasaki N; Goto T; Wang L; Terada N
Cell Biochem Biophys; 2014 Sep; 70(1):521-7. PubMed ID: 24744183
[TBL] [Abstract][Full Text] [Related]
2. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
3. [Inhibitory effect of ONO-AE3-208 on the formation of bone metastasis of prostate cancer in mice].
Xu S; Ge JP; Zhou WQ; Zhang ZY
Zhonghua Nan Ke Xue; 2014 Aug; 20(8):684-9. PubMed ID: 25195362
[TBL] [Abstract][Full Text] [Related]
4. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.
Yang L; Huang Y; Porta R; Yanagisawa K; Gonzalez A; Segi E; Johnson DH; Narumiya S; Carbone DP
Cancer Res; 2006 Oct; 66(19):9665-72. PubMed ID: 17018624
[TBL] [Abstract][Full Text] [Related]
5. [Novel treatment for prostate cancer targeting prostaglandins].
Terada N; Inoue T; Kamba T; Ogawa O
Nihon Rinsho; 2014 Dec; 72(12):2141-6. PubMed ID: 25518348
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases.
Watanabe K; Tominari T; Hirata M; Matsumoto C; Maruyama T; Murphy G; Nagase H; Miyaura C; Inada M
Biochem Biophys Res Commun; 2016 Sep; 478(1):154-161. PubMed ID: 27450806
[TBL] [Abstract][Full Text] [Related]
7. The PGE(2)-EP4 receptor is necessary for stimulation of the renin-angiotensin-aldosterone system in response to low dietary salt intake in vivo.
Pöschke A; Kern N; Maruyama T; Pavenstädt H; Narumiya S; Jensen BL; Nüsing RM
Am J Physiol Renal Physiol; 2012 Nov; 303(10):F1435-42. PubMed ID: 22993066
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis.
Ma X; Kundu N; Rifat S; Walser T; Fulton AM
Cancer Res; 2006 Mar; 66(6):2923-7. PubMed ID: 16540639
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells.
Takita M; Inada M; Maruyama T; Miyaura C
FEBS Lett; 2007 Feb; 581(3):565-71. PubMed ID: 17254571
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells.
Prijatelj M; Celhar T; Mlinaric-Rascan I
Prostaglandins Other Lipid Mediat; 2011 Aug; 95(1-4):19-26. PubMed ID: 21600299
[TBL] [Abstract][Full Text] [Related]
11. Blockade of prostaglandin E
Aringer I; Artinger K; Kirsch AH; Schabhüttl C; Jandl K; Bärnthaler T; Mooslechner AA; Herzog SA; Uhlig M; Kirsch A; Frank S; Banas M; Pollheimer M; Eller P; Rosenkranz AR; Heinemann A; Eller K
Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1869-F1880. PubMed ID: 30332316
[TBL] [Abstract][Full Text] [Related]
12. Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer.
Huang HF; Shu P; Murphy TF; Aisner S; Fitzhugh VA; Jordan ML
Mol Cancer Res; 2013 Apr; 11(4):427-39. PubMed ID: 23364535
[TBL] [Abstract][Full Text] [Related]
13. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
[TBL] [Abstract][Full Text] [Related]
14. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.
Monet M; Lehen'kyi V; Gackiere F; Firlej V; Vandenberghe M; Roudbaraki M; Gkika D; Pourtier A; Bidaux G; Slomianny C; Delcourt P; Rassendren F; Bergerat JP; Ceraline J; Cabon F; Humez S; Prevarskaya N
Cancer Res; 2010 Feb; 70(3):1225-35. PubMed ID: 20103638
[TBL] [Abstract][Full Text] [Related]
15. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
16. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells.
Wu GJ; Peng Q; Fu P; Wang SW; Chiang CF; Dillehay DL; Wu MW
Gene; 2004 Mar; 327(2):201-13. PubMed ID: 14980717
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin receptor EP4 in abdominal aortic aneurysms.
Cao RY; St Amand T; Li X; Yoon SH; Wang CP; Song H; Maruyama T; Brown PM; Zelt DT; Funk CD
Am J Pathol; 2012 Jul; 181(1):313-21. PubMed ID: 22595380
[TBL] [Abstract][Full Text] [Related]
19. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR
J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805
[TBL] [Abstract][Full Text] [Related]
20. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Glenn JR; White AE; Iyu D; Heptinstall S
Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
